Joyner J. David 4/A
4/A · CVS HEALTH Corp · Filed Dec 26, 2024
Insider Transaction Report
Form 4/AAmended
Joyner J. David
DirectorPresident and CEO
Transactions
- Award
Premium Stock Appreciation Right
2024-11-30$71.82/sh+492,537$35,374,007→ 492,537 totalExercise: $71.82From: 2025-11-30Exp: 2031-11-30→ Common Stock (492,537 underlying) - Award
Premium Stock Option
2024-11-30$71.82/sh+1,000,000$71,820,000→ 1,000,000 totalExercise: $71.82From: 2025-11-30Exp: 2031-11-30→ Common Stock (1,000,000 underlying)
Holdings
- 44,241
Common Stock (Restricted)
- 40,681
Common Stock
Footnotes (1)
- [F1]On December 20, 2024, the Issuer made certain administrative modifications to the Reporting Person's November 30, 2024 grant agreement, confirming that the Reporting Person was granted a stock option to acquire 1,000,000 shares of Issuer common stock and a stock-settled stock appreciation right ("SAR") with respect to 492,537 shares of Issuer common stock, each at a premium exercise or grant price, as applicable, of $71.82. Both the option and the SAR become exercisable in three equal annual installments, with the first installment vesting on November 30, 2025. No change was made to the aggregate grant date value of the award, as reflected in the original Form 4 filed by the Reporting Person on December 3, 2024.